The development of the etoposidecisplatin regimen

The EP regimen was developed by investigators at MSKCC. In an early trial of patients who had good-risk metastatic GCT, EP was compared with the VAB-6 regimen (cisplatin, vinblastine, bleomycin, dactinomycin, cyclophosphamide) [12]. Although these regimens had similar efficacy, the toxicity profile and ease of administration of the EP regimen was superior. At MSKCC, four cycles of EP became the standard for patients who had good-risk metastatic GCT.

Investigators at MSKCC recently reported a retrospective analysis of long-term follow-up on 289 patients who had good-risk metastatic GCT defined by IGCCC criteria [13]. Complete response was achieved in 98% of patients. Five-year survival for the cohort was 96% (95% CI, 94%-98%). Based on these excellent results, four cycles of EP is now considered an alternate to three cycles of BEP.

0 0

Post a comment